Trial reportObesity (Silver Spring, Md.)2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Trial report in Obesity (Silver Spring, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 219 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program
The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy
Who cites it
219 citing papers in PubMed, 15 syntheses or guidelines pooled it, 538 citations in OpenAlex.
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2026Guideline
- iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025.Journal of cachexia, sarcopenia and muscle · 2026Guideline
- Pooled it
- The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: a systematic review.Psychopharmacology · 2025Pooled it
- Obesity in South and Southeast Asia-A new consensus on care and management.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2023Guideline
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Long-term effects of weight-reducing drugs in people with hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.British journal of clinical pharmacology · 2020Pooled it
- Identification and Management of Cardiometabolic Risk after Spinal Cord Injury.The journal of spinal cord medicine · 2019Guideline
- Pooled it
- Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.Topics in spinal cord injury rehabilitation · 2018Guideline
- Food cue reactivity and craving predict eating and weight gain: a meta-analytic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2016Pooled it
- European Guidelines for Obesity Management in Adults.Obesity facts · 2015 · on this mapGuideline
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.Drug design, development and therapy · 2014Pooled it
- Long-term drug treatment for obesity: a systematic and clinical review.JAMA · 2014 · on this mapPooled it
- Trial
- Addition of Phentermine-Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double-Blind Randomized Clinical Trial.Obesity (Silver Spring, Md.) · 2026Trial
- Characterization of the effect of naltrexone/bupropion on body composition.Diabetes, obesity & metabolism · 2025Trial
- Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.Nature medicine · 2025Trial
- Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.Psychological medicine · 2023Trial
159 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 1 country.
Funding
Abstract
This 56-week, randomized, placebo-controlled trial examined the efficacy and safety of naltrexone plus bupropion as an adjunct to intensive behavior modification (BMOD). A total of 793 participants (BMI = 36.5 ± 4.2 kg/m²) was randomly assigned in a 1:3 ratio to: (i) placebo + BMOD (N = 202); or (ii) naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD (i.e., NB32 + BMOD; N = 591). Both groups were prescribed an energy-reduced diet and 28 group BMOD sessions. Co-primary end points were percentage change in weight and the proportion of participants who lost ≥5% weight at week 56. Efficacy analyses were performed on a modified intent-to-treat population (ITT; i.e., participants with ≥1 postbaseline weight while taking study drug (placebo + BMOD, N = 193; NB32 + BMOD, N = 482)). Missing data were replaced with the last observation obtained on study drug. At week 56, weight loss was 5.1 ± 0.6% with placebo + BMOD vs. 9.3 ± 0.4% with NB32 + BMOD (P < 0.001). A completers analysis revealed weight losses of 7.3 ± 0.9% (N = 106) vs. 11.5 ± 0.6% (N = 301), respectively (P < 0.001). A third analysis, which included all randomized participants, yielded losses of 4.9 ± 0.6 vs. 7.8 ± 0.4%, respectively (P < 0.001). Significantly more NB32 + BMOD- vs. placebo + BMOD-treated participants lost ≥5 and ≥10% of initial weight, and the former had significantly greater improvements in markers of cardiometabolic disease risk. NB32 + BMOD was generally well tolerated, although associated with more reports of nausea than placebo + BMOD. The present findings support the efficacy of combined naltrexone/bupropion therapy as an adjunct to intensive BMOD for obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.